賽倫生物(688163.SH):目前抗蛇毒血清原液出口的主要地區爲韓國
格隆匯6月17日丨賽倫生物(688163.SH)在互動平臺表示,(1)公司目前抗蛇毒血清原液出口的主要地區爲韓國。公司密切關注海外市場相關信息,如有明確的進度計劃,將會按照相關規則及時進行披露。 (2)公司產品系抗狂犬病血清,非狂犬病疫苗。2024 年末,公司啓動了抗狂犬病血清上市銷售的準備工作,截至目前,已在多個省份採購信息平臺提交掛網申請,目前處於等待審覈中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.